Olive Jung is a predoctoral Intramural Research Training Award (IRTA) fellow in the 3-D Tissue Bioprinting Program of the Early Translation Branch within NCATS’ Division of Preclinical Innovation. In this position, she is working to develop relevant tissue models that can be used in drug screenings and that are predictive of clinical trial outcomes.
Prior to joining NCATS, Jung completed her first two years of medical school at Case Western Reserve University as part of her M.D.-D.Phil. training and will return to medical school to complete the last two years after finishing the doctoral program at the National Institutes of Health (NIH) and the University of Oxford. Prior to her M.D.-D.Phil. training, Jung worked from 2015 to 2017 as a postbaccalaureate IRTA fellow at NCATS and the National Human Genome Research Institute through a trans-Institute/Center collaboration between Juan Jose Marugan, Ph.D., and Ellen Sidransky, M.D.
Jung received her bachelor’s degree, with honors, in chemistry from Northwestern University in 2015 and worked under the supervision of Richard B. Silverman, Ph.D., during her undergraduate research career in medicinal chemistry.
Jung is completing her D.Phil. degree through the NIH-Oxford/Cambridge Scholars Program — a four-year accelerated doctoral program designed to enhance international collaboration between the NIH and universities in the United Kingdom. Currently, she is part of the 3-D Tissue Bioprinting subgroup working on the Helping to End Addiction Long-termSM Initiative, or the NIH HEAL InitiativeSM, as well as the COVID-19 efforts, building flow-based blood-brain barrier models and vascularized alveoli-capillary models. Her goal is to utilize these platforms for high-throughput screening and to increase applicability of these 3-D tissue models for pathomechanistic and drug delivery studies.